


This listing of claims will replace all prior versions and listings in the application:

**Listing of Claims:**

1. (currently amended) A compound of formula (I), or an enantiomer or diastereoisomer thereof:



(I)

wherein:

A is a 5- or 6-membered ~~homocyclic~~ carbocyclic ring;


X is H and W is OH; or X and W together form a carbonyl group or an epoxide;

R<sup>1</sup> is H; or one or two substituents independently selected from the group consisting of: hydroxy; halo; lower alkyl; lower alkoxy; lower thioalkyl; haloalkyl (e.g. trifluoromethyl); or -C(O)R<sup>2</sup> wherein R<sup>2</sup> is lower alkyl, aryloxy or benzyloxy;

Y is phenyl optionally mono- or di-substituted with R<sup>5</sup> or C(O)R<sup>6</sup>, wherein R<sup>5</sup> is lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile or trifluoromethyl, and R<sup>6</sup> is lower alkyl, lower cycloalkyl, lower alkoxy, hydroxy or trifluoromethyl; said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered carbocyclic ring ~~optionally containing a heteroatom selected from N, O and S~~;

or Y is ethylene-phenyl, said ethylene moiety being optionally mono-substituted with lower alkyl, wherein said phenyl ring is optionally mono- or di-substituted with R<sup>5</sup> or C(O)R<sup>6</sup>, wherein R<sup>5</sup> and R<sup>6</sup> are as defined above; said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered carbocyclic ring ~~optionally containing a heteroatom selected from N, O and S~~;






wherein A, X, R<sup>1</sup>, Y, R<sup>3</sup>, and R<sup>4</sup> are as defined in claim 1.

3. (original) A mixture of compound I(a) and compound I(b), according to claim 2.
4. (original) A mixture of compound I(c) and compound I(d), according to claim 2.
5. (previously presented) A compound mixture according to claim 3, wherein said mixture is racemic.
6. (previously presented) A compound mixture according to claim 4, wherein said mixture is racemic.
7. (previously presented) A compound I(a) according to claim 2, as a pure enantiomer.
8. (previously presented) A compound I(c) according to claim 2, as a pure enantiomer.
9. (original) A compound according to claim 1 wherein X is H and W is OH; or X and W form a carbonyl group.

10. (original) A compound according to claim 9 wherein X and W form a carbonyl group.
11. (previously presented) A compound according to claim 1 wherein ring A is a benzene ring, as represented by the formula I':



wherein X, R<sup>1</sup>, W, Y, R<sup>3</sup>, and R<sup>4</sup> are as defined in claim 1.


12. (cancelled)
13. (original) A compound according to claim 1, wherein R<sup>1</sup> is H; or one or two substituents independently selected from the group consisting of: hydroxy; halo; lower alkyl; lower alkoxy; lower thioalkyl; haloalkyl; or -C(O)R<sup>2</sup> wherein R<sup>2</sup> is lower alkyl, aryloxy or benzyloxy.
14. (original) A compound according to claim 13, wherein R<sup>1</sup> is H, halo or C<sub>1-4</sub> alkyl.
15. (original) A compound according to claim 14, wherein R<sup>1</sup> is H, fluoro or methyl.
16. (original) A compound according to claim 15, wherein R<sup>1</sup> is H or methyl.

17. (currently amended) A compound according to claim 1, wherein Y is phenyl optionally mono- or di-substituted with  $R^5$  or  $C(O)R^6$ , wherein  $R^5$  is lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile or trifluoromethyl, and  $R^6$  is lower alkyl, lower cycloalkyl, lower alkoxy, hydroxy or trifluoromethyl; said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered carbocyclic ring ~~optionally containing a heteroatom selected from N, O and S~~; or Y is ethylene-phenyl, said ethylene moiety being optionally mono-substituted with lower alkyl, wherein said phenyl ring is optionally mono- or di-substituted with  $R^5$  or  $C(O)R^6$ , wherein  $R^5$  and  $R^6$  are as defined above; said phenyl ring being optionally fused with a saturated or unsaturated 4- to 6-membered carbocyclic ring ~~optionally containing a heteroatom selected from N, O and S~~.

18. (original) A compound according to claim 17, wherein Y is naphthyl,  $CH=CH$ -phenyl,  $C(CH_3)=CH$ -phenyl or phenyl, wherein the phenyl ring is optionally mono- or di-substituted at the 3, 4, or 5 position with  $R^5$ , wherein  $R^5$  is halo,  $C_{1-4}$  alkyl, hydroxy,  $CF_3$  or  $NHC(O)$ -(lower alkyl).

19. (currently amended) A compound according to claim 18, wherein Y is phenyl optionally substituted with: 3,4-Cl; 3-F,4-Cl; 3-Cl,4-F; 3,4-Br; 3-F,4- $CH_3$ ; 3,4- $CH_3$ ;

3- $CF_3$  or;  $NHC(O)$ -( $CH_2$ ) $_3$  $CH_3$  ~~and~~




20. (currently amended) A compound according to claim 19, wherein Y is phenyl optionally substituted with: 3,4-Cl ~~and~~ or 3,4-Br.

21. (currently amended) A compound according to claim 1, wherein  $R^3$  is :  
( $C_{1-6}$  alkyl)phenyl wherein the phenyl ring is optionally substituted with:

~~Het~~morpholine, said ~~Het~~morpholine optionally mono- or di-substituted with lower alkyl, lower alkoxy, halo, hydroxy, nitrile or trifluoromethyl;


22. (currently amended) A compound according to claim 21, wherein R<sup>3</sup> is selected from:



23. (cancelled)











24. (cancelled)

25. (currently amended) A compound selected from the group consisting of: compounds having the following formula:




, wherein R<sup>4A</sup>, R<sup>1</sup>, R<sup>5</sup> and R<sup>3</sup> are as defined as follows:









Cpd #	R <sup>4A</sup>	R <sup>1</sup>	--R <sup>5</sup>	--R <sup>3</sup>
1028	Na	—	3,4-Cl	

Cpd #	R <sup>4A</sup>	R <sup>1</sup>	--R <sup>5</sup>	--R <sup>3</sup>
1034	Na	--	3,4-Cl	
1052	Na	--	3,4-Cl	
1059	Na	--	3,4-F	
1076	Na	--	3,4-Br	
1078	Na	--	3,4-Br	
1083	Na	--	3,4-F	
1085	Na	--	3-CN	
1128	Na	--	3,4-Cl	
1143	Na	b-F	3,4-Br	
1144	Na	c-F	3,4-Br	






26. (currently amended) A compound selected from the group consisting of:  
compounds having the following formula:




wherein R<sup>4A</sup>, R<sup>1</sup>, R<sup>5</sup>, and R<sup>3</sup> are as defined as follows:

Cpd #	R <sup>4A</sup>	R <sup>1</sup>	--R <sup>5</sup>	--R <sup>3</sup>	
A1001	Na	--	3,4-Br	 stereochemistry undetermined	5
A1002	Na	--	3,4-Br	 stereochemistry undetermined	5
A1006	Na	mixture b-Me & e-Me	3,4-Cl	 stereochemistry undetermined	5
A1007	Na	b-Me	3,4-Cl	 stereochemistry undetermined	5
A1008	Na	e-Me	3,4-Cl	 stereochemistry undetermined	5
A1009	Na	mixture b-Me & e-Me	3,4-Br	 stereochemistry undetermined	5
A1010	Na	b-Me	3,4-Br	 stereochemistry undetermined	5
A1011	Na	e-Me	3,4-Br	 stereochemistry undetermined	5







Cpd #	R <sup>4A</sup>	R <sup>1</sup>	--R <sup>5</sup>	--R <sup>3</sup>	
A1012	Na	--	3,4-Br		;
				stereochemistry undetermined	
A1013	Na	--	3,4-Br		;
				stereochemistry undetermined	
A1014	Na	c-Me	3,4-Br		;
A1015	Na	b-F, c-Me	3,4-Br		; and
A1016	Na	b-Me, c-F	3,4-Br		.

27. (previously presented) A compound selected from the group consisting of:  
compounds having the following formula:



wherein R<sup>1</sup>, R<sup>5</sup>, and R<sup>3</sup> are as defined as follows:


Cpd #	R <sup>1</sup>	R <sup>5</sup>	R <sup>3</sup>	
B1001	b-Me, c-Me (mixture)	3,4-Br		;

B1002	b-Me	3,4-Br	 ;
B1003	c-Me	3,4-Br	 ; and
B1008	b-F, c-Me	3,4-Br	 .


28. (cancelled)

29. (cancelled)


30. (previously presented) A compound selected from the group consisting of:  
compounds having the following formula:



wherein  $R^5$  and  $R^3$  are as defined as follows:

Cpd #	-- $R^5$	--- $R^3$
2023	3,4-Br	

31. (currently amended) A compound selected from the group consisting of:  
compounds having the following formula:




wherein R<sup>1</sup>, Y, and R<sup>3</sup> are as defined as follows:

Cpd #	R <sup>1</sup>	--Y	--R <sup>3</sup>
3013	e-Me		
3016	b-F		
3017	c-F		

Claims 32-37 (cancelled)

38. (original) A compound having the following formula:



wherein Y and R<sup>3</sup> are as defined as follows:

Cpd #	--Y	--R <sup>3</sup>
10,001		

39. (original) A pharmaceutical composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I), according to claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

40. (previously presented) A method for treating a papillomavirus viral infection in a mammal by administering to the mammal an anti-papilloma virus virally effective amount of a compound of formula (I), according to claim 1, or a therapeutically acceptable salt or ester thereof, or a pharmaceutical composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I) according to claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

41. (previously presented) A method for inhibiting the replication of papillomavirus by exposing the virus to an amount of a compound of formula (I), according to claim 1 inhibiting the papilloma virus E1-E2-DNA complex, or a therapeutically acceptable salt or ester thereof, or a composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I) according to claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

42. (previously presented) A method of preventing perinatal transmission of HPV from mother to baby, by administering a compound of formula (I), according to claim 1, to the mother prior to giving birth.

Claims 43-53 (cancelled)

54. (previously presented) A compound I(b) according to claim 2, as a pure enantiomer.

55. (previously presented) A compound I(d) according to claim 2, as a pure enantiomer.